Centogene publication in brain journal reveals 15% of parkinson's disease cases are linked to genetic factors

Cambridge, mass. and rostock, germany and berlin, aug. 01, 2024 (globe newswire) -- centogene n.v. (nasdaq: cntg), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced data from the company's rostock international parkinson's disease (ropad) study revealing the genetic factors and prevalence of parkinson's disease (pd). the findings from this landmark study indicate that approximately 15% of pd-related cases are tied to genetic variants, with the majority being linked to lrrk2 and gba1. the data was published in brain in a paper titled, “relevance of genetic testing in the gene-targeted trial era: the rostock parkinson's disease study.”
CNTG Ratings Summary
CNTG Quant Ranking